Time-kill study of the activity of trovafloxacin compared with ciproffoxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 23-27

  Spangler, S K ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SPARFLOXACIN; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTEROIDES; BACTEROIDES FRAGILIS; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; DILUTION; DOSE TIME EFFECT RELATION; FUSOBACTERIUM; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PREVOTELLA; SOLUTION AND SOLUBILITY; SUSPENSION;

EID: 0030756869     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.23     Document Type: Article

References (21)

1. Barry, A. L. & Fuchs, P. C. (1991). In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin and fleroxacin. Antimicrobial Agents and Chemotherapy 35, 955-60.
2. Barry, A. L., Fuchs, P. C., Citron, D. M., Allen, S. D. & Wexler, H. M. (1993). Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. Journal of Antimicrobial Chemotherapy 31, 893-900.
3. Bauernfeind, A. (1993). Comparative in-vitro activities of the new quinolone, Bay y3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. Journal of Antimicrobial Chemotherapy 31, 505-22.
4. Ueno, K., Watanabe, K., Kato, N., Kato, H., Bandoh, K. & Tanaka, Y. (1992). Comparative in vitro activity of AM-1155, a new quinolone, against anaerobic bacteria. In Program and Abstracts of the Fourth International Symposium on New Quinolones, Munich 1992. Abstract 26, p. 32.
5. Ueno, K., Watanabe, K., Kato, N., Muto, Y., Bandoh, K. & Oka, M. (1991). OPC-17116, a novel quinolone: in vitro activity against anaerobic bacteria. In Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1467, p. 343. American Society for Microbiology, Washington, DC.
6. Appelbaum, P. C. (1995). Quinolone activity against anaerobes: microbiological aspects. Drugs 49, Suppl. 2, 76-80.
7. Goldstein, E. J. C. & Citron, D. M. (1992). Comparative activity of ciprofloxacin, ofloxacin, spartloxacin, temafloxacin, CI-960, CI990, and Win 57273 against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 36, 1158-62.
8. Kato, N., Watanabe, K., Kato, H., Tanaka, K., Tanaka, Y. & Ueno, K. (1993). Comparative in vitro activity of DU-6859a, a new quinolone, against anaerobic bacteria. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1993. Abstract 990, p. 300. American Society for Microbiology, Washington, DC.
9. Jones, R. N. & Erwin, M. E. (1992). In vitro activity of CP-74667 compared with four other fluoroquinolones. Diagnostic Microbiology and Infectious Disease 15, 531-6.
10. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
11. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
12. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin/ tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.
13. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1994). Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrobial Agents and Chemotherapy 38, 2065-72.
14. Jacobs, M. R., Spangler, S. K. & Appelbaum, P. C. (1992). Beta-lactamase production and susceptibility of US and European anaerobic Gram-negative bacilli to beta-lactams and other agents. European Journal of Clinical Microbiology & Infectious Diseases 11, 1081-93.
15. Holdeman, L V., Cato, E. P. & Moore, W. E. C. (1977). Anaerobe Laboratory Manual, 4th edn. Virginia Polytechnic Institute and State University, Blacksburg, VA.
16. Summanen, P., Baron, E. J., Citron, D. M., Strong, C. A., Wexler, H. M. & Finegold, S. M. (1993). Wadsworih Anaerobic Bacteriology Manual, 5th edn, Star Publishing Co., Belmont, CA.
17. National Committee for Clinical Laboratory Standards. (1993). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Third Edition; Approved Standard M11-A3, NCCLS, Villanova, PA.
18. Appelbaum, P. C., Spangler, S. K. & Jacobs, M. R. (1993). Susceptibility of 539 Gram-positive and Gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. Journal of Antimicrobial Chemotherapy 32, 223-31.
19. Spangler, S, K., Jacobs, M. R. & Appelbaum, P. C. (1995). Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by Oxyrase agar dilution and E test methodologies. Journal of Clinical Microbiology 33, 1366-7.
20. 2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin and roxithromycin. Antimicrobial Agents and Chemotherapy 38, 211-6.
21. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.